These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 24800916)

  • 1. Double heterozygotes among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN/NBS1, and BLM germ-line mutations.
    Sokolenko AP; Bogdanova N; Kluzniak W; Preobrazhenskaya EV; Kuligina ES; Iyevleva AG; Aleksakhina SN; Mitiushkina NV; Gorodnova TV; Bessonov AA; Togo AV; Lubiński J; Cybulski C; Jakubowska A; Dörk T; Imyanitov EN
    Breast Cancer Res Treat; 2014 Jun; 145(2):553-62. PubMed ID: 24800916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rare key functional domain missense substitutions in MRE11A, RAD50, and NBN contribute to breast cancer susceptibility: results from a Breast Cancer Family Registry case-control mutation-screening study.
    Damiola F; Pertesi M; Oliver J; Le Calvez-Kelm F; Voegele C; Young EL; Robinot N; Forey N; Durand G; Vallée MP; Tao K; Roane TC; Williams GJ; Hopper JL; Southey MC; Andrulis IL; John EM; Goldgar DE; Lesueur F; Tavtigian SV
    Breast Cancer Res; 2014 Jun; 16(3):R58. PubMed ID: 24894818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in
    Yadav S; Boddicker NJ; Na J; Polley EC; Hu C; Hart SN; Gnanaolivu RD; Larson N; Holtegaard S; Huang H; Dunn CA; Teras LR; Patel AV; Lacey JV; Neuhausen SL; Martinez E; Haiman C; Chen F; Ruddy KJ; Olson JE; John EM; Kurian AW; Sandler DP; O'Brien KM; Taylor JA; Weinberg CR; Anton-Culver H; Ziogas A; Zirpoli G; Goldgar DE; Palmer JR; Domchek SM; Weitzel JN; Nathanson KL; Kraft P; Couch FJ
    J Clin Oncol; 2023 Mar; 41(9):1703-1713. PubMed ID: 36623243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical findings and clinicopathological features of breast cancers with pathogenic germline mutations in Non-BRCA genes.
    Singh K; Scalia J; Legare R; Quddus MR; Sung CJ
    Hum Pathol; 2024 Apr; 146():49-56. PubMed ID: 38608781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene panel testing of 5589 BRCA1/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer.
    Hauke J; Horvath J; Groß E; Gehrig A; Honisch E; Hackmann K; Schmidt G; Arnold N; Faust U; Sutter C; Hentschel J; Wang-Gohrke S; Smogavec M; Weber BHF; Weber-Lassalle N; Weber-Lassalle K; Borde J; Ernst C; Altmüller J; Volk AE; Thiele H; Hübbel V; Nürnberg P; Keupp K; Versmold B; Pohl E; Kubisch C; Grill S; Paul V; Herold N; Lichey N; Rhiem K; Ditsch N; Ruckert C; Wappenschmidt B; Auber B; Rump A; Niederacher D; Haaf T; Ramser J; Dworniczak B; Engel C; Meindl A; Schmutzler RK; Hahnen E
    Cancer Med; 2018 Apr; 7(4):1349-1358. PubMed ID: 29522266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study.
    Joris S; Denys H; Collignon J; Rasschaert M; T'Kint de Roodenbeke D; Duhoux FP; Canon JL; Tejpar S; Mebis J; Decoster L; Aftimos P; De Grève J
    ESMO Open; 2023 Dec; 8(6):102041. PubMed ID: 37852034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic profiling of CHEK2*1100delC-mutated breast carcinomas.
    Massink MP; Kooi IE; Martens JW; Waisfisz Q; Meijers-Heijboer H
    BMC Cancer; 2015 Nov; 15():877. PubMed ID: 26553136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted next generation sequencing identifies functionally deleterious germline mutations in novel genes in early-onset/familial prostate cancer.
    Paulo P; Maia S; Pinto C; Pinto P; Monteiro A; Peixoto A; Teixeira MR
    PLoS Genet; 2018 Apr; 14(4):e1007355. PubMed ID: 29659569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted genotyping for recurring variants in cancer susceptibility genes in non-Ashkenazi Jewish patients with breast cancer diagnosed ≥50 years.
    Bernstein-Molho R; Shhada NA; Laitman Y; Netzer I; Shoval S; Friedman E
    Cancer; 2024 Aug; 130(16):2763-2769. PubMed ID: 38630906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast cancer screening implications of risk modeling among female relatives of ATM and CHEK2 carriers.
    Weidner AE; Liggin ME; Zuniga BI; Tezak AL; Wiesner GL; Pal T
    Cancer; 2020 Apr; 126(8):1651-1655. PubMed ID: 31967672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers.
    Weigelt B; Bi R; Kumar R; Blecua P; Mandelker DL; Geyer FC; Pareja F; James PA; ; Couch FJ; Eccles DM; Blows F; Pharoah P; Li A; Selenica P; Lim RS; Jayakumaran G; Waddell N; Shen R; Norton L; Wen HY; Powell SN; Riaz N; Robson ME; Reis-Filho JS; Chenevix-Trench G
    J Natl Cancer Inst; 2018 Sep; 110(9):1030-1034. PubMed ID: 29506079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical relevance of double heterozygosity revealed by next-generation sequencing of homologous recombination repair pathway genes in South African breast cancer patients.
    van der Merwe NC; Buccimazza I; Rossouw B; Araujo M; Ntaita KS; Schoeman M; Vorster K; Napo K; Kotze MJ; Oosthuizen J
    Breast Cancer Res Treat; 2024 Sep; 207(2):331-342. PubMed ID: 38814507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study.
    Broeks A; Braaf LM; Huseinovic A; Nooijen A; Urbanus J; Hogervorst FB; Schmidt MK; Klijn JG; Russell NS; Van Leeuwen FE; Van 't Veer LJ
    Breast Cancer Res; 2007; 9(2):R26. PubMed ID: 17428320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathologic and genetic analysis of invasive breast carcinomas in women with germline CHEK2 variants.
    Schwartz CJ; Khorsandi N; Blanco A; Mukhtar RA; Chen YY; Krings G
    Breast Cancer Res Treat; 2024 Feb; 204(1):171-179. PubMed ID: 38091153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and characterization of ATM founder mutation in BRCA-negative breast cancer patients of Arab ethnicity.
    Bu R; Siraj AK; Al-Rasheed M; Iqbal K; Azam S; Qadri Z; Haqawi W; Tulbah A; Al-Dayel F; Almalik O; Al-Kuraya KS
    Sci Rep; 2023 Nov; 13(1):20924. PubMed ID: 38017116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical interpretation of pathogenic ATM and CHEK2 variants on multigene panel tests: navigating moderate risk.
    West AH; Blazer KR; Stoll J; Jones M; Weipert CM; Nielsen SM; Kupfer SS; Weitzel JN; Olopade OI
    Fam Cancer; 2018 Oct; 17(4):495-505. PubMed ID: 29445900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High risk of breast cancer in women with biallelic pathogenic variants in CHEK2.
    Rainville I; Hatcher S; Rosenthal E; Larson K; Bernhisel R; Meek S; Gorringe H; Mundt E; Manley S
    Breast Cancer Res Treat; 2020 Apr; 180(2):503-509. PubMed ID: 31993860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A qualitative study of unaffected ATM and CHEK2 carriers: How participants make meaning of 'moderate risk' genetic results in a population breast cancer screening trial.
    James JE; Riddle L; Caruncho M; Koenig BA; Joseph G
    J Genet Couns; 2022 Dec; 31(6):1421-1433. PubMed ID: 35877161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk.
    Liu J; Lončar I; Collée JM; Bolla MK; Dennis J; Michailidou K; Wang Q; Andrulis IL; Barile M; Beckmann MW; Behrens S; Benitez J; Blomqvist C; Boeckx B; Bogdanova NV; Bojesen SE; Brauch H; Brennan P; Brenner H; Broeks A; Burwinkel B; Chang-Claude J; Chen ST; Chenevix-Trench G; Cheng CY; Choi JY; Couch FJ; Cox A; Cross SS; Cuk K; Czene K; Dörk T; Dos-Santos-Silva I; Fasching PA; Figueroa J; Flyger H; García-Closas M; Giles GG; Glendon G; Goldberg MS; González-Neira A; Guénel P; Haiman CA; Hamann U; Hart SN; Hartman M; Hatse S; Hopper JL; Ito H; Jakubowska A; Kabisch M; Kang D; Kosma VM; Kristensen VN; Le Marchand L; Lee E; Li J; Lophatananon A; Jan Lubinski ; Mannermaa A; Matsuo K; Milne RL; ; Neuhausen SL; Nevanlinna H; Orr N; Perez JI; Peto J; Putti TC; Pylkäs K; Radice P; Sangrajrang S; Sawyer EJ; Schmidt MK; Schneeweiss A; Shen CY; Shrubsole MJ; Shu XO; Simard J; Southey MC; Swerdlow A; Teo SH; Tessier DC; Thanasitthichai S; Tomlinson I; Torres D; Truong T; Tseng CC; Vachon C; Winqvist R; Wu AH; Yannoukakos D; Zheng W; Hall P; Dunning AM; Easton DF; Hooning MJ; van den Ouweland AM; Martens JW; Hollestelle A
    Sci Rep; 2016 Nov; 6():36874. PubMed ID: 27845421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Penetrance of ATM Gene Mutations in Breast Cancer: A Meta-Analysis of Different Measures of Risk.
    Marabelli M; Cheng SC; Parmigiani G
    Genet Epidemiol; 2016 Jul; 40(5):425-31. PubMed ID: 27112364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.